Zhang X, Wang Y, Zhao W, Yang S, Moussian B, Zhao Z
Cells. 2024; 13(14.
PMID: 39056781
PMC: 11274743.
DOI: 10.3390/cells13141199.
Zhou Y, Liu F, Ma C, Cheng Q
J Clin Lab Anal. 2022; 36(10):e24673.
PMID: 36036748
PMC: 9551129.
DOI: 10.1002/jcla.24673.
Xing M, Wang X, Kiken R, He L, Zhang J
Int J Mol Sci. 2021; 22(11).
PMID: 34200243
PMC: 8201127.
DOI: 10.3390/ijms22116139.
Zou C, Yuan C, Ye J, Liu Z, Gao X, Piao X
Am J Transl Res. 2020; 12(9):5683-5695.
PMID: 33042448
PMC: 7540149.
Liu X, Gao F, Jiang L, Jia M, Ao L, Lu M
J Transl Med. 2020; 18(1):295.
PMID: 32746924
PMC: 7398316.
DOI: 10.1186/s12967-020-02462-1.
Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma.
Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H
Virusdisease. 2019; 30(2):193-200.
PMID: 31179356
PMC: 6531550.
DOI: 10.1007/s13337-019-00517-6.
Hepatocellular Carcinoma: Causes, Mechanism of Progression and Biomarkers.
Singh A, Kumar R, Pandey A
Curr Chem Genom Transl Med. 2018; 12:9-26.
PMID: 30069430
PMC: 6047212.
DOI: 10.2174/2213988501812010009.
Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis.
Zhang J, Zhang M, Ma H, Song X, He L, Ye X
Medicine (Baltimore). 2018; 97(24):e11130.
PMID: 29901640
PMC: 6024095.
DOI: 10.1097/MD.0000000000011130.
Prognostic significance of glypican-3 expression in hepatocellular carcinoma: A meta-analysis.
Liu H, Yang C, Lu W, Zeng Y
Medicine (Baltimore). 2018; 97(4):e9702.
PMID: 29369198
PMC: 5794382.
DOI: 10.1097/MD.0000000000009702.
Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.
Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M
J Hepatocell Carcinoma. 2017; 4:93-103.
PMID: 28744453
PMC: 5513853.
DOI: 10.2147/JHC.S106529.
Biomarkers for Hepatocellular Carcinoma.
Lou J, Zhang L, Lv S, Zhang C, Jiang S
Biomark Cancer. 2017; 9:1-9.
PMID: 28469485
PMC: 5345949.
DOI: 10.1177/1179299X16684640.
Biomarkers for the early diagnosis of hepatocellular carcinoma.
Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T
World J Gastroenterol. 2015; 21(37):10573-83.
PMID: 26457017
PMC: 4588079.
DOI: 10.3748/wjg.v21.i37.10573.
Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3.
Kawashima I, Kawashima Y, Matsuoka Y, Fujise K, Sakai H, Takahashi M
Clin Case Rep. 2015; 3(6):444-7.
PMID: 26185646
PMC: 4498860.
DOI: 10.1002/ccr3.279.
Hypervascular hepatocellular carcinomas showing hyperintensity on hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging: a possible subtype with mature hepatocyte nature.
Yoneda N, Matsui O, Kitao A, Kita R, Kozaka K, Koda W
Jpn J Radiol. 2013; 31(7):480-90.
PMID: 23771695
DOI: 10.1007/s11604-013-0224-6.
Peptide vaccines for hepatocellular carcinoma.
Nobuoka D, Yoshikawa T, Sawada Y, Fujiwara T, Nakatsura T
Hum Vaccin Immunother. 2013; 9(1):210-2.
PMID: 23442593
PMC: 3667940.
DOI: 10.4161/hv.22473.
Hepatocellular tumors: immunohistochemical analyses for classification and prognostication.
Lo R, Ng I
Chin J Cancer Res. 2013; 23(4):245-53.
PMID: 23359751
PMC: 3551308.
DOI: 10.1007/s11670-011-0245-6.
Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients.
Ning S, Bin C, Na H, Peng S, Yi D, Xiang-hua Y
Mol Biol Rep. 2011; 39(1):351-7.
PMID: 21655958
DOI: 10.1007/s11033-011-0745-y.
Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S
Cancer Sci. 2009; 100(8):1403-7.
PMID: 19496787
PMC: 11158276.
DOI: 10.1111/j.1349-7006.2009.01206.x.
Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair endochondral ossification and cause recessive omodysplasia.
Campos-Xavier A, Martinet D, Bateman J, Belluoccio D, Rowley L, Tan T
Am J Hum Genet. 2009; 84(6):760-70.
PMID: 19481194
PMC: 2694977.
DOI: 10.1016/j.ajhg.2009.05.002.